Loading stock data…
C4 Therapeutics (CCCC)
$3.55-0.21 (-5.59%)
Market ClosedLast close Sep 8
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
C4 Therapeutics, Inc. in the Healthcare sector is trading at $3.55 with a market capitalization of $406M. Wall Street consensus targets $13.33 (6 analysts), implying a +275.6% move over the next 12 months. The stock is currently 31% below its 52-week high of $5.17, remaining 16.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +275.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.15M↓ | $11.02M↓ | $11.23M↑ | $6.46M↓ | $7.24M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$27.79M↓ | -$23.14M↑ | -$23.68M↑ | -$28.50M↑ | -$29.16M |
| Net Income | -$25.13M↓ | -$20.49M↑ | -$32.17M↓ | -$26.02M↑ | -$26.32M |
Peer Comparison
JNJUNHPFE
Fundamentals
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$406.33M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-44.31%
Volume
Today's trading volume
2.17M
Recent News
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +21.74% and +10.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?
C4 Therapeutics, Inc. (NASDAQ:CCCC) has gained roughly 16% over the past month, mainly driven by positive phase 1 clinical trial data for Cemsidomide. The data was presented on June 11, following which the stock rose more than 13%. The Street expects more than 158% upside from the current level, making C4 one of the BBest […]